Co-Diagnostics (CODX) Tops Q2 EPS by $1.54, Beats on Revenue

Co-Diagnostics (NASDAQ: CODX) reported Q2 EPS of ($1.46), $1.54 better than the analyst estimate of ($3.00). Revenue for the quarter came in at $170 thousand versus the consensus estimate of $132.58 thousand.

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.

You May Also Be Interested In

• Canaccord Starts BillionToOne Inc (BLLN) at Buy
• Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance
• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance